Allevion Therapeutics

Allevion operates at the intersection of wearable medical devices, neuromodulation, and digital therapeutics, targeting essential tremor rather than broad consumer wellness. Its Allevx Smart-Band is differentiated in the profile by a non-invasive, multi-modal smart energy approach delivered through a wrist-worn form factor, with stated expansion potential into Parkinson’s disease and dystonia. In the broader tremor-management market, Cala Health is a relevant named peer because it also uses wrist-worn neuromodulation, while Liftware represents a different non-invasive approach focused on stabilizing utensils for people with hand tremor. Its $1.475 million in recorded funding and 11-to-50 employee classification indicate an early-stage profile relative to better-known commercial device companies.

Allevion’s trajectory shows a long development cycle with financing activity spanning 2018 to 2024. The company was founded in 2018, following Shawn Moaddeb’s reported start as CEO and Board Chairman in March 2017. Adventus Ventures led the May 2018 seed round, followed by an undisclosed private equity round on Sep 23, 2020 and a $1.475 million undisclosed financing announced on Mar 26, 2024. The sequence suggests continued capital formation around development of the Allevx Smart-Band, but the absence of disclosed amounts for two rounds makes cumulative capital beyond $1.475 million difficult to quantify. The company is classified in the 11-to-50 employee range, although only one current leadership position is specifically identified. The main potential inflection point is the transition from a patented device concept to validated clinical, regulatory, and commercial deployment.